Cargando…

Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey

INTRODUCTION: Patient adherence is a major challenge for the successful management of any chronic disease, and ulcerative colitis (UC) is no exception. Patient adherence is closely related to patient preference of medication and formulation used. AIM: The aim of this study was to investigate patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hébuterne, Xavier, Vavricka, Stephan R., Thorne, Helen C., MacKenzie-Smith, Lara, Laoun, Raphaël, Burisch, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498945/ https://www.ncbi.nlm.nih.gov/pubmed/37711959 http://dx.doi.org/10.1159/000530139

Ejemplares similares

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
por: D’Haens, Geert, et al.
Publicado: (2023)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Mild to moderate ulcerative colitis: Call me by my name
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
por: Attauabi, Mohamed, et al.
Publicado: (2023)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Health-Related Quality of Life in Chinese Patients with Mild and Moderately Active Ulcerative Colitis
por: Zheng, Kai, et al.
Publicado: (2015)

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis
por: Huang, Chunlan, et al.
Publicado: (2022)

Mild-to-Moderate Ulcerative Colitis: Your Role in Patient Compliance and Health Care Costs
por: Tindall, William N., et al.
Publicado: (2007)

Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus
por: Awadhi, Sameer Al, et al.
Publicado: (2023)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

Periodontitis prevalence in patients with ulcerative colitis and Crohn's disease ‐ PPCC: A case–control study
por: Bertl, Kristina, et al.
Publicado: (2022)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Vitamin D Status and Its Relation to Inflammatory Markers in Patients with Mild to Moderate Ulcerative Colitis
por: Sharifi, Amrollah, et al.
Publicado: (2018)

Vitamin D Increases CTLA-4 Gene Expression in Patients with Mild to Moderate Ulcerative Colitis
por: Sharifi, Amrollah, et al.
Publicado: (2019)

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
por: Cheon, Jae Hee, et al.
Publicado: (2023)

Risk factors for complications in patients with ulcerative colitis
por: Manser, Christine N, et al.
Publicado: (2016)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Combined Diosmectite and Mesalazine Treatment for Mild-to-Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Study
por: Jiang, Xue-Liang, et al.
Publicado: (2015)

High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis
por: Winter, Harland S., et al.
Publicado: (2014)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
por: Jeon, Seong Ran
Publicado: (2018)

Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010–2014
por: Akhuemonkhan, Eboselume, et al.
Publicado: (2017)

The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis
por: Tian, Chunying, et al.
Publicado: (2020)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
por: Kobayashi, Taku, et al.
Publicado: (2021)

Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis
por: Tripathi, Kartikeya, et al.
Publicado: (2021)

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T., et al.
Publicado: (2017)

Factor-XIII activity in patients with mild to moderate ulcerative colitis and active bleeding: a prospective observational study
por: Bernerth, Karsten, et al.
Publicado: (2018)

A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study
por: Sarbagili-Shabat, Chen, et al.
Publicado: (2021)

The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe
por: Ruiz-Casas, Leonardo, et al.
Publicado: (2021)

Patient and physician preferences for ulcerative colitis treatments in the United States
por: Boeri, Marco, et al.
Publicado: (2019)

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T, et al.
Publicado: (2017)

Traditional Chinese medicine for mild-to-moderate ulcerative colitis: Protocol for a network meta-analysis of randomized controlled trials
por: Shen, Zhaofeng, et al.
Publicado: (2019)

Fecal Filobasidium Is Associated with Clinical Remission and Endoscopic Response following Fecal Microbiota Transplantation in Mild-to-Moderate Ulcerative Colitis
por: van Thiel, Isabelle A. M., et al.
Publicado: (2022)

Safety and Potential Role of Lactobacillus rhamnosus GG Administration as Monotherapy in Ulcerative Colitis Patients with Mild–Moderate Clinical Activity
por: Pagnini, Cristiano, et al.
Publicado: (2023)

Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study
por: Safroneeva, Ekaterina, et al.
Publicado: (2015)

Correction to: The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe
por: Ruiz-Casas, Leonardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aatfapisphndskd3qej3i29mpo